Moderna Climbs 3% Despite Citigroup's Downgrade to Sell; BioNTech Inches Higher, Pfizer Treads Water

Buyers are stepping into Moderna (NASDAQ:MRNA | MRNA Price Prediction) shares, evidently. The move comes one session after a Citigroup (NYSE:C) downgrade to Sell, a sign the market still prizes the company's cancer vaccine pipeline over the valuation warning.